Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, ...

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in ...

Genentech is letting go of 118 employees in San Francisco. The news comes about two months after the biotech ended a ...

Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

Aldeyra has since resubmitted its application, buffing it up with a “single clinical trial that achieved the primary endpoint ...

Eli Lilly and Johnson & Johnson are joining fellow Big Pharma peers in upping their investment in AI, with Lilly looking to ...

As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; ...

While the FDA continues to put out guidance documents and approve drugs, some companies are already reporting delays in ...

Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...

Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal ...

Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well ...